All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR and Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked about measuring disease modification in MPN clinical trials.
Barbui begins by discussing established response criteria and the multi-parameter context of disease modification in myeloproliferative neoplasms, summarizing surrogate and non-surrogate markers. He highlights the complex situation in myelofibrosis compared with polycythemia vera and essential thrombocytosis in this regard.
Kiladjian then raises the challenges around these parameters and opens a discussion on whether artificial intelligence would be useful for a more objective and standardized response assessment in clinical trials.
They also touch upon measuring the molecular response inflammation in disease modification.
Measuring disease modification in MPN clinical trials
Editorial theme | Progression in myeloproliferative neoplasms
This editorial theme article will discuss the clinical characteristics of progression of myeloproliferative neoplasms (MPN) and the risk factors associated with progression.
How should we define disease modification in MF?
During the ESH 9th Translational Research Conference: Myeloproliferative Neoplasms, the MPN Hub was pleased to speak to Naveen Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, How should we...
Subscribe to get the best content related to MPN delivered to your inbox